Regulation of Inflammation by the Fibrinolytic System

纤溶系统对炎症的调节

基本信息

  • 批准号:
    9285496
  • 负责人:
  • 金额:
    $ 38.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-04-10 至 2021-03-31
  • 项目状态:
    已结题

项目摘要

Hemostasis and immunity are highly interrelated systems. Dysregulation of hemostasis, thrombosis, and dis- seminated intravascular coagulation (DIC) are serious complications observed in patients with trauma, sterile tissue injury, systemic inflammation, and sepsis. This research project focuses on a novel pathway by which the major intravascular activator of fibrinolysis, tissue-type Plasminogen Activator (tPA), controls innate im- munity and inflammation. LDL Receptor-related Protein-1 (LRP1) is an endocytic and cell-signaling receptor for tPA. When LRP1 is deleted conditionally in myeloid cells in mice, the inflammatory response to lipopoly- saccharide/endotoxin (LPS) is greatly exacerbated. In LRP1-deficient macrophages, NFκB is activated and expression of pro-inflammatory cytokines is robustly increased. microRNA-155 expression also is increased, which may sustain inflammation, as is expression of the Serpin fibrinolysis inhibitors, plasminogen activator inhibitor-1 (PAI-1) and PAI-2, which contribute to a pro-thrombotic state. In macrophages that express LRP1, different ligands that bind to LRP1 have opposite effects on macrophage phenotype and gene expression, a phenomenon that we hypothesize reflects ligand-specific recruitment of macrophage co-receptors, including N- methyl-D-aspartate Receptor. tPA-binding to LRP1 is anti-inflammatory. Enzymatically-inactive tPA (EI-tPA) blocks the toxicity of LPS in wild-type mice. The anti-inflammatory activity of tPA represents a novel and unanticipated activity of an FDA-approved drug. The major objective of this grant application is to elucidate the activity of tPA in inflammation and a novel pathway by which tPA may counteract development of thrombosis in tissue injury and sepsis. Three specific aims are proposed. In Specific Aim 1, we apply a systems biology approach to elucidate the anti-inflammatory signaling pathway activated by EI-tPA-binding to LRP1 in macro- phages. Specific attention will be dedicated to identifying co-receptors, systems of signaling proteins that func- tion concomitantly to regulate gene expression, and gene products such as SOCS1 and SOCS3, which may determine whether the effects of tPA on inflammation are sustained. In Specific Aim 2, we test the hypothesis that tPA suppresses inflammation in response to multiple stimuli by examining two alternative model systems in mice, lipoteichoic acid challenge and the passive K/BxN serum-transfer arthritis model, in which innate im- munity is activated by Fc receptors and complement factors. In Specific Aim 3, we test the hypothesis that EI- tPA may counteract development of pro-thrombotic states in conditions such as trauma and sepsis by controlling gene expression in macrophages. Proposed experiments in Specific Aim 3 focus on the balance between plasminogen activators and their inhibitors and on cell-surface receptors that promote plasminogen activation by tPA. Overall, this project offers an opportunity to further our understanding of crosstalk between fibrinolysis and cellular systems that control inflammation. The novel pathways under investigation may yield new targets for drug development in chronic inflammation and hemostasis.
止血和免疫是高度相关的系统。止血、血栓和血管紊乱

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEVEN L. GONIAS其他文献

STEVEN L. GONIAS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEVEN L. GONIAS', 18)}}的其他基金

A novel role for Reelin therapeutics in inflammatory bowel disease
Reelin 疗法在炎症性肠病中的新作用
  • 批准号:
    10079713
  • 财政年份:
    2020
  • 资助金额:
    $ 38.75万
  • 项目类别:
Regulation of Inflammation by the Fibrinolytic System
纤溶系统对炎症的调节
  • 批准号:
    10358335
  • 财政年份:
    2017
  • 资助金额:
    $ 38.75万
  • 项目类别:
Regulation of Inflammation by the Fibrinolytic System
纤溶系统对炎症的调节
  • 批准号:
    9913997
  • 财政年份:
    2017
  • 资助金额:
    $ 38.75万
  • 项目类别:
Regulation of Inflammation by the Fibrinolytic System
纤溶系统对炎症的调节
  • 批准号:
    10557130
  • 财政年份:
    2017
  • 资助金额:
    $ 38.75万
  • 项目类别:
Regulation of Inflammation by the Fibrinolytic System
纤溶系统对炎症的调节
  • 批准号:
    10693590
  • 财政年份:
    2017
  • 资助金额:
    $ 38.75万
  • 项目类别:
Targeting the Urokinase Receptor in Glioblastoma Multiforme
靶向多形性胶质母细胞瘤中的尿激酶受体
  • 批准号:
    8613477
  • 财政年份:
    2013
  • 资助金额:
    $ 38.75万
  • 项目类别:
Targeting the Urokinase Receptor in Glioblastoma Multiforme
靶向多形性胶质母细胞瘤中的尿激酶受体
  • 批准号:
    8501950
  • 财政年份:
    2013
  • 资助金额:
    $ 38.75万
  • 项目类别:
Targeting the Urokinase Receptor in Glioblastoma Multiforme
靶向多形性胶质母细胞瘤中的尿激酶受体
  • 批准号:
    9023503
  • 财政年份:
    2013
  • 资助金额:
    $ 38.75万
  • 项目类别:
Targeting the Urokinase Receptor in Glioblastoma Multiforme
靶向多形性胶质母细胞瘤中的尿激酶受体
  • 批准号:
    9215655
  • 财政年份:
    2013
  • 资助金额:
    $ 38.75万
  • 项目类别:
Urokinase Receptor-initiated Cell-signaling
尿激酶受体启动的细胞信号传导
  • 批准号:
    7909207
  • 财政年份:
    2009
  • 资助金额:
    $ 38.75万
  • 项目类别:

相似海外基金

AcT-Cog: Online cognitive assessment in the Alteplase compared to Tenecteplase (AcT) trial.
AcT-Cog:阿替普酶与替奈普酶 (AcT) 试验相比的在线认知评估。
  • 批准号:
    444794
  • 财政年份:
    2021
  • 资助金额:
    $ 38.75万
  • 项目类别:
    Operating Grants
INTERRAcT: Thrombus characteristics for predicting Reperfusion with Alteplase compared to Tenecteplase
INTERRAcT:与替奈普酶相比,阿替普酶预测再灌注的血栓特征
  • 批准号:
    433102
  • 财政年份:
    2020
  • 资助金额:
    $ 38.75万
  • 项目类别:
    Operating Grants
Alteplase Compared to Tenecteplase in patients with Acute Ischemic Stroke: QuICR & OPTIMISE Registry based Pragmatic Randomized Controlled Trial
阿替普酶与替奈普酶治疗急性缺血性中风患者的比较:QuICR
  • 批准号:
    401715
  • 财政年份:
    2019
  • 资助金额:
    $ 38.75万
  • 项目类别:
    Operating Grants
Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial
替奈普酶与阿替普酶用于中风溶栓评估 (TASTE) 试验
  • 批准号:
    nhmrc : 1079696
  • 财政年份:
    2015
  • 资助金额:
    $ 38.75万
  • 项目类别:
    Project Grants
Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial
替奈普酶与阿替普酶用于中风溶栓评估 (TASTE) 试验
  • 批准号:
    nhmrc : GNT1079696
  • 财政年份:
    2015
  • 资助金额:
    $ 38.75万
  • 项目类别:
    Project Grants
Low-Dose Tenecteplase vs Standard-Dose Alteplase for Acute Ischaemic Stroke: An Imaging Based Safety and Efficacy Study
低剂量替奈普酶与标准剂量阿替普酶治疗急性缺血性中风:一项基于影像学的安全性和有效性研究
  • 批准号:
    nhmrc : 510722
  • 财政年份:
    2008
  • 资助金额:
    $ 38.75万
  • 项目类别:
    NHMRC Project Grants
Treament of Deep Vein Thrombosis with Alteplase
阿替普酶治疗深静脉血栓
  • 批准号:
    7004919
  • 财政年份:
  • 资助金额:
    $ 38.75万
  • 项目类别:
Treatment of Deep Vein Thrombosis of the Lower Extremities w/Low Dose Alteplase
小剂量阿替普酶治疗下肢深静脉血栓
  • 批准号:
    8565339
  • 财政年份:
  • 资助金额:
    $ 38.75万
  • 项目类别:
Treament of Deep Vein Thrombosis of the Lower Extremities w/Low Dose Alteplase
小剂量阿替普酶治疗下肢深静脉血栓
  • 批准号:
    7593114
  • 财政年份:
  • 资助金额:
    $ 38.75万
  • 项目类别:
Treatment of Deep Vein Thrombosis of the Lower Extremities w/Low Dose Alteplase
小剂量阿替普酶治疗下肢深静脉血栓
  • 批准号:
    8952839
  • 财政年份:
  • 资助金额:
    $ 38.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了